In our hands, differently from most of the previous studies using HPV vaccine-LRT combinations, combining E7 RNA-LPX with LRT timidly modulated the E7 RNA-LPX-primed E7-specific CD8+T cell response in magnitude, but rather boosted and sustained their anti-tumor efficacy and effector function at later time points during tumor rejection. Here, CD8A is linked to neoplasm.